Loading...

Analysts Trim Prestige Consumer Healthcare Price Target Amid Guidance Cut and Buyback Activity

Published
03 Sep 24
Updated
21 Oct 25
AnalystConsensusTarget's Fair Value
US$80.80
22.7% undervalued intrinsic discount
21 Oct
US$62.49
Loading
1Y
-12.9%
7D
1.0%

Author's Valuation

US$80.822.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on21 Oct 25
Fair value Decreased 2.42%

Analysts have slightly reduced their price target for Prestige Consumer Healthcare from $82.80 to $80.80. This change is due to marginal adjustments to projected valuation metrics and profit assumptions.

Shared on11 Aug 25
Fair value Decreased 6.97%

The consensus Analyst Price Target for Prestige Consumer Healthcare was lowered to $82.80, primarily reflecting reduced revenue growth expectations and a slight contraction in net profit margin. What's in the News Prestige Consumer Healthcare is actively seeking M&A opportunities, leveraging strong free cash flow and reduced leverage.

Shared on08 May 25
Fair value Increased 0.56%

Shared on30 Apr 25
Fair value Increased 0.99%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 2.77%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 1.99%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Decreased 0.15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.